Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenalidomide + dexamethasone + MEDI-551
- Development stage
- Phase 1
- Lead developer
- Bristol Myers Squibb
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
This combination involves **lenalidomide**, a structural analogue of thalidomide used in treating multiple myeloma; **dexamethasone**, a corticosteroid; and **MEDI-551**, a monoclonal antibody targeting CD19. Lenalidomide works by modulating the immune system and inhibiting angiogenesis. Dexamethasone is used for its anti-inflammatory and immunosuppressive effects. MEDI-551 depletes B cells by targeting CD19, which may be beneficial in reducing cancer stem cells in multiple myeloma.
02
Targets
Beyond the preview
Go deeper on lenalidomide + dexamethasone + MEDI-551.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenalidomide + dexamethasone + MEDI-551.